Rich Stuart 4
4 · TENAX THERAPEUTICS, INC. · Filed Jan 27, 2021
Insider Transaction Report
Form 4
Rich Stuart
DirectorChief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2021-01-15+250,000→ 250,000 totalExercise: $1.78Exp: 2031-01-15→ Common Stock (250,000 underlying) - Award
Common Stock
2021-01-15+662,517→ 662,517 total - Award
Series B Preferred Stock
2021-01-15+3,581→ 3,581 total
Footnotes (2)
- [F1]The reporting person acquired the securities in connection with the merger of PHPrecisionMed Inc. with and into a wholly owned subsidiary of Tenax Therapeutics, Inc. (the "Transaction").
- [F2]The option becomes exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA.